Curis Announces Presentation at Cowen & Company 39th Annual Healthcare Conference

Monday, March 4, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

LEXINGTON, Mass., March 4, 2019 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the

development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer, will present at the Cowen & Company 39th Annual Healthcare Conference
on Wednesday, March 13th, at 11:20 a.m.11:50 a.m. EST in the Berkeley room at the Marriott Copley in Boston, MA.

A live webcast of the presentation will be available on the Company's website: www.curis.com. The webcast will be archived for 90 days.

About Curis, Inc.  Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.

Cision View original content:http://www.prnewswire.com/news-releases/curis-announces-presentation-at-cowen--company-39th-annual-healthcare-conference-300803212.html

SOURCE Curis, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store